Fujifilm has acquired a large-scale biologics site near Copenhagen, Denmark.
The company paid $890 million in cash for the former Biogen-owned campus, which consists of a manufacturing facility with six 15,000L bioreactors capable of churning out cell culture-derived biologics for clinical and commercial use. The campus also includes facilities for packaging and labeling, quality control, assembly, labs and warehouses.
Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm and a CDMO that specializes in biologics and advanced therapies, now owns four manufacturing sites. About 800 employees work at the new Danish site.
Read the press release.
Don't miss your Daily Dose. Get news like this delivered right to your inbox.